Patient and clinician perspectives on pharmacogenetic testing for antipsychotics.

ABSTRACT:

Background/objectives

Medications to treat psychosis (i.e., antipsychotics) have common and sometimes serious adverse drug reactions and can require several trials before finding a suitable drug and dose. To address this, there is increasing focus on personalizing medicine. Pharmacogenetics investigates how genetic variation influences drug metabolism and response, with recent clinical trials suggesting pharmacogenetic testing can improve remission and reduce adverse drug reactions. Therefore, understanding stakeholder perspectives on acceptability is critical.

Methods

This pilot study is part of 'GEMS' (Genetics and Environment in Mental Health Study), which investigates pharmacogenetic testing for psychosis. A participant survey, co-created with patients, was completed by

SUBMITTER: Richards-Brown M 

PROVIDER: S-EPMC12547232 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature